Syndax Pharmaceuticals (SNDX) Stock Forecast, Price & News

Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions

Is Syndax Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Syndax Pharmaceuticals stock.
View analyst ratings for Syndax Pharmaceuticals or view top-rated stocks.

When is Syndax Pharmaceuticals' next earnings date?

Syndax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Syndax Pharmaceuticals.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced its earnings results on Monday, May, 9th. The company reported ($0.63) earnings per share for the quarter, hitting the consensus estimate of ($0.63). Syndax Pharmaceuticals had a trailing twelve-month return on equity of 5.18% and a net margin of 17.84%. During the same period in the previous year, the company posted ($0.54) EPS.
View Syndax Pharmaceuticals' earnings history.

What price target have analysts set for SNDX?

3 Wall Street analysts have issued twelve-month price objectives for Syndax Pharmaceuticals' stock. Their forecasts range from $21.00 to $40.00. On average, they expect Syndax Pharmaceuticals' stock price to reach $30.67 in the next twelve months. This suggests a possible upside of 87.9% from the stock's current price.
View analysts' price targets for Syndax Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Syndax Pharmaceuticals' key executives?

Syndax Pharmaceuticals' management team includes the following people:

• Mr. Michael A. Metzger M.B.A., CEO & Director (Age 51, Pay $899.15k)
• Dr. Briggs W. Morrison M.D., Pres, Head of R&D and Director (Age 62, Pay $935.84k)
• Dr. Anjali Ganguli Ph.D., Chief Bus. Officer (Age 46, Pay $450.58k)
• Dr. Peter Ordentlich B.Sc., Ph.D., Co-Founder & Chief Scientific Officer (Age 53) (LinkedIn Profile)
• Dr. Richard A. Heyman Ph.D., Co-Founder (Age 65)
• Dr. Ronald M. Evans Ph.D., Co-Founder, Advisor and Chair of Scientific Advisory Board
• Dr. Michael Downes Ph.D., Co-Founder
• Mr. Alexander Nolte, Interim Principal Financial Officer, VP & Chief Accounting Officer (Age 49) (LinkedIn Profile)
• Mr. Luke J. Albrecht, Sr. VP, Gen. Counsel & Sec. (Age 42)
• Dr. Michael L. Meyers M.D., Ph.D., Consultant (Age 71) (LinkedIn Profile)

Who are some of Syndax Pharmaceuticals' key competitors?

Some companies that are related to Syndax Pharmaceuticals include CureVac (CVAC), Arrowhead Pharmaceuticals (ARWR), Cytokinetics (CYTK), Bausch Health Companies (BHC), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC), Karuna Therapeutics (KRTX), Pacira BioSciences (PCRX), Zai Lab (ZLAB), Indivior (INVVY), Prestige Consumer Healthcare (PBH), ACADIA Pharmaceuticals (ACAD), Harmony Biosciences (HRMY), EQRx (EQRX) and Insmed (INSM).
View all of SNDX's competitors.

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.90%), Frazier Life Sciences Management L.P. (5.68%), Nantahala Capital Management LLC (4.79%), Vanguard Group Inc. (4.33%), State Street Corp (4.23%) and Kynam Capital Management LP (3.44%). Company insiders that own Syndax Pharmaceuticals stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Michael A Metzger, Michael L Meyers, Peter Ordentlich and Pierre Legault.
View institutional ownership trends for Syndax Pharmaceuticals.

Which major investors are selling Syndax Pharmaceuticals stock?

SNDX stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Citigroup Inc., State Street Corp, Ghost Tree Capital LLC, Gyon Technologies Capital Management LP, BNP Paribas Arbitrage SA, Metropolitan Life Insurance Co NY, and Royal Bank of Canada. Company insiders that have sold Syndax Pharmaceuticals company stock in the last year include Alexander Nolte, Briggs Morrison, Fabrice Egros, Michael A Metzger, Peter Ordentlich, and Pierre Legault.
View insider buying and selling activity for Syndax Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Syndax Pharmaceuticals stock?

SNDX stock was purchased by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., Kynam Capital Management LP, Paradigm Biocapital Advisors LP, Wellington Management Group LLP, Phoenix Holdings Ltd., Renaissance Technologies LLC, BlackRock Inc., and Vanguard Group Inc.. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Dennis Podlesak, and Michael L Meyers.
View insider buying and selling activity for Syndax Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $16.32.

How much money does Syndax Pharmaceuticals make?

Syndax Pharmaceuticals has a market capitalization of $917.71 million and generates $139.71 million in revenue each year. The company earns $24.93 million in net income (profit) each year or $0.339990 on an earnings per share basis.

How many employees does Syndax Pharmaceuticals have?

Syndax Pharmaceuticals employs 59 workers across the globe.

What is Syndax Pharmaceuticals' official website?

The official website for Syndax Pharmaceuticals is www.syndax.com.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at (781) 419-1400, via email at [email protected], or via fax at 781-419-1420.